重组人表皮生长因子应用于肛裂手术的临床研究

目的：研究外源性表皮生长因子对于肛裂手术后的手术创面愈合情况的影响。方法：肛裂手术后，治疗组患者每日用重组人表皮生长因子敷于肛管创面，对照组患者采用常规的方式换药。比较两组患者术后伤口疼痛、出血情况，以及伤口肉芽生长愈合情况。结果：治疗组在减轻术后伤口疼痛、伤口水肿和出血等方面均显著优于对照组，其平均住院时间和伤口愈合时间也显著短于对照组。结论：外源性表皮生长因子有助于肛裂术后创面的快速修复，减轻患者的痛苦。     

重组人表皮生长因子对促进Ⅱ度烧伤愈合的作用

目的 探讨重组人表皮生长因子(rhEGF)对促进Ⅱ度烧伤创面愈合的作用。方法 采用自身对照研究方法,选取46例Ⅱ度烧伤患者观察最适治疗浓度创面局部应用的治疗效果及不良反应。结果 在浅Ⅱ度烧伤创面,观察组的愈合时间为(8.7±2.1)天,对照组为(12.2±2.4)天,而深Ⅱ度烧伤创面观察组的愈合时间是(13.4±2.6)天,对照组为(19.2±3.2)天。与对照组相比,观察组创面愈合时间均有明显缩短(P<0.01),结论 rhEGF对Ⅱ度烧伤创面均可有效地促进组织修复,加快创面愈合速度,有良好的促进愈合作用,而药物反应极轻微。     

辐照猪皮与金因肽联合在儿童烧伤创面治疗中的应用

目的：观察辐照猪皮与金因肽在儿童Ⅱ度烧伤治疗中的作用。方法：治疗组清创后应用辐照猪皮与金因肽覆盖创面;对照组应用磺胺嘧啶银锌霜＋金因肽覆盖创面。临床选择65例患者（总共127个创面）,包括浅、深Ⅱ度烧伤,临床观察创面愈合时间、应用辐照猪皮与金因肽对全身情况的影响,后期瘢痕增生情况。结果：治疗组比对照组创面愈合时间明显缩短,治疗组明显优于对照组（P〈0.05）;患者未出现过敏反应和其他不良反应,后期随访瘢痕增生少。结论：辐照猪皮与金因肽联合治疗儿童Ⅱ度烧伤创面,可促进创面上皮化,明显缩短创面愈合时间,瘢痕增生少,疗效可靠。     

重组人表皮细胞生长因子对人皮肤细胞增殖作用的研究

目的：观察重组人表皮生长因子（recombinant human epidermal growth factor，rhEGF）对人表皮细胞增殖的变化。方法：运用包皮环切术后收集培养角质细胞，不同浓度的重组人表皮细胞生长因子处理细胞，MTT法测细胞生长率；流式细胞仪检测细胞周期以及蛋白的表达。结果：5～10ng·ml^-1重组人表皮细胞生长因子可促进人表皮细胞细胞生长。流式细胞仪检测10ng·ml^-1重组人表皮细胞生长因子处理后细胞增殖明显，S和G2／M期细胞数明显增加。结论：重组人表皮细胞生长因子可促进细胞生长以及切口愈合。     

Effect of protease inhibitors on degradation of recombinant human epidermal growth factor in skin tissue

Recombinant human epidermal growth factor (rhEGF), a polypeptide of 53 amino acid residues, is subject to degradation by numerous enzymes, especially proteases, when it is applied on the skin for the treatment of open wound. Amastatin, aprotinin, bestatin, EDTA, EGTA, gabexate, gentamicin, leupeptin, and TPCK were investigated for the possible protease inhibitors, which may use to protect rhEGF from degradation by the enzymes in the skin. Skin homogenates containing protease inhibitors and rhEGF were incubated at 37°C for 30 minutes. After the reaction was stopped with trifluoroacetic acid, the amount of rhEGF remaining in the sample was determined with an HPLC method. The percentages of rhEGF degraded, at the skin/PBS ratio of 0.25, in the mouse, rat, and human skin homogenate were 85%, 70%, and 46%, respectively. The degree of degradation of rhEGF in the cytosolic fraction was higher than that in the membrane fraction and these enzyme reactions were completed in 30 minutes. Bestatin, EGTA, and TPCK showed significant inhibitory effects on the degradation of rhEGF in the two fractions (p<0.05), while the other protease inhibitors had no significant inhibitory effects or, even resulted in deleterious effects. Therefore, the formulation containing one or several inhibitors among these effective inhibitors would be a promising topical preparation of rhEGF for the treatment of open wound.     

表皮生长因子导入治疗在皮肤扩张器中的应用研究

目的:探讨使用导入仪导入重组人表皮生长因子(rhEGF)促进皮肤扩张的临床效果。方法:自2013年1月~2013年5月入选38例患者,共将76个扩张器进行埋置,按照随机原则,分为常规注水对照组(36个扩张器)与导入仪导入治疗组(36个扩张器)。治疗组的扩张器在每次注水扩张的第二天进行导入仪治疗,在被扩张的皮肤表面涂抹rhEGF并使用导入按摩仪进行按摩导入。对照组的扩张器仅进行常规的注水。测量两组扩张器扩张致额定容量所花费的时间、皮肤扩张比率及扩张皮肤即刻回缩比率,采用自身对照的方法进行比较分析。进行胶原含量,I/III型胶原比率(%)的测定和病理HE染色分析。结果:注水后第二天进行rhEGF导入治疗能使扩张器扩张致额定容量所花费的时间明显缩短,皮肤扩张比率则明显增加,扩张皮肤即刻回缩比率减少,有效减小皮辨的即时回缩率。治疗组胶原纤维束粗而密,I/III型胶原比例降低。结论:注水后第二天通过使用导入仪将rhEGF导入扩张皮肤治疗能缩短扩张时程,促进皮肤的面积增加,降低皮瓣回缩的比率,提高皮瓣质量,改善治疗效果。     

LED红光联合重组人表皮生长因子治疗面部激素依赖性皮炎的疗效观察

目的 探讨LED红光联合重组人表皮生长因子治疗面部激素依赖性皮炎的疗效.方法 收集40例面部激素依赖性皮炎患者,随机将患者分为联合治疗组和对照组各20例.联合治疗组患者给予LED红光照射治疗,20分/次,2次/周.每次照射后给予重组人表皮生长因子外用溶液湿敷20分钟.对照组仅单独给予LED红光照射治疗,20分/次,2次...     

鼻咽癌患者放射治疗前局部冰敷减轻口腔黏膜反应的效果

目的探讨鼻咽癌放射治疗前局部冰敷对口腔黏膜反应的影响。方法 将80例首程放射治疗鼻咽癌患者随机分为试验组和对照组,每组40例。试验组在放疗前将冰袋置于照射野皮肤30min,然后立即进行放射治疗。对照组行常规护理,不进行冰敷。口腔出现黏膜溃疡时,首先用无菌棉签擦干口腔溃疡处,再喷涂重组人表皮生长因子(rhEGF),每天2次。放射治疗第7周,对患者口咽部采样进行微生物学监测。结果放射治疗第3周末、第7周末、结束后1周,试验组口腔黏膜炎明显轻于对照组。咽拭子细菌培养阳性率试验组(17.5%)低于对照组(37.5%)。结论放射治疗前局部冰敷可有效预防与减轻鼻咽癌放射治疗所致口腔黏膜反应,减少口腔真菌感染。     

金因肽联合半导体激光治疗复发性口腔溃疡临床观察

目的探讨金因肽联合半导体激光治疗复发性口腔溃疡的临床效果。方法将100例复发性口腔溃疡患者随机分为实验组和对照组各50例。对照组使用金因肽1喷/次,3次/d;实验组在对照组的基础上增加半导体激光的照射治疗,照射6 min/次,1次/d,对两组疼痛消失、溃疡愈合和复发率情况进行对比。结果疼痛消失的时间实验组(2.99±0.35)d,对照组(4.33±0.47)d,两组比较差异有统计学意义(P<0.05);溃疡愈合时间实验组(4.60±0.75)d,对照组(6.38±0.76)d,两组比较差异有统计学意义(P<0.05);口腔溃疡的复发率实验组4.00%,对照组16.00%,两组比较差异有统计学意义(P<0.05)。结论金因肽联合半导体激光治疗复发性口腔溃疡可以缩短疼痛和愈合时间,减少复发频率,具有应用价值。     

重组人表皮生长因子衍生物对准分子激光上皮下角膜磨镶术后角膜上皮修复临床观察

目的 准分子激光上皮下角膜磨镶术(LASEK)后早期使用重组牛碱性成纤维细胞人生长因子(金因舒rhEGF),通过临床观察术后反应,评价外源兴表皮生长因子促进角膜上皮修复的作用.方法 采用随机、双盲、对照的原则,治疗组50例(50眼)均为左眼,采用金因舒+0.1%氟美瞳+0.3%泰利必妥,对照组50例(50眼)均为左眼,单用0.1%氟美瞳+0.3%泰利必.术后观察疼痛、畏光、流泪、异物感、球结膜充血、角膜上皮混浊6项指标.按无、轻、中、重分别记为0、1、2、3分.术后1、2、3、5 d观察术后反应并评分,术后1、2、3周检查视力,术后1、2、3个月观察角膜雾状混浊(Haze)发生情况.第5天开始根据指征尽早取镜.结果 术后第1天和第2天治疗组术后反应较轻,与对照组比较差异有统计学意义(P<0.05).治疗组平均取镜时间为5.5 d,对照组为6.12 d,治疗组早于对照组.两组恢复最佳视力的时间比较差异无统计学意义,术后Haze的发生率和严重程度比较差异无统计学意义.结论 重组人表皮生长因子衍生物能减轻术后早期反应,缩短术后绷带镜片的佩戴时间,安全、无不良反应,有助于LASEK术后角膜上皮化学性和机械性损伤的修复. Abstract： Objective To evaluate the effect of ectogenous recombinant human growth factor eye drops(rhEGF) on cutting section corncal epithelium recovery after laser epithelial keratomileusis(LASEK)by observing postoperative inflammation clinically. Methods A randomized, double-blindly,comparison group controlled study enrolled 50 pstients(50eyes,all left eyes) for rhEGF group with therapy of rhEGF+0.1% fluorometholone+0.3% ofloxacin and 50 patients(50eyes,all left eyes) for controlled group with therapy of 0.1% florometholone+0.3% ofloxacin.Observeing pain,photophobia, tearing, foreign body sensation, conjunctival congest and corneal epithelial opacity were observed at 1, 2, 3 and 5 days postoperatively and scored as 0, 1, 2 or 3 respectively according to negative, slight, moderate or severe degree. Visual acuity was measured at 1, 2 and 3 weeks postoperatively. The corneal haze was exanined at 1,2 and 3months postoperatively. The band contact lenses were removed as early as possible from 5 days postoperatively. Results Postoperative inflammation of rhEGF group was significantly slighter than comparison group at 1 and 2 days postoperatively (P<0.05) Average time of removing contact lens was 5.5 days and 6.12 days for treated two group respectively. There was no difference on the time of achieving best visual acuity and haze between two groups. Conclusions rhEGF may relieve early inflammation postoperatively after LASEK and shorten the time of wearing contact lenses, beneficial to epithelium recovery from chemical and machinical injury.